DEM BioPharma is a Massachusetts-based biotechnology company that develops and commercializes immunotherapeutics for the treatment of cancer. They are pioneering the next generation of immunotherapeutics designed to unleash macrophages and other myeloid effector cells to eliminate tumors by targeting novel ‘don’t eat me’ (DEM) and ‘eat me’ (EM) signals on cancer cells and macrophages. Their proprietary CHoMP™ platform (Co-culture with Human Myeloid Phagocytes) will be used to develop a pipeline of products that target the tumor microenvironment.
However, their primary competitors include Turnstone Biologics, ImmunityBio, Immatics and 26 more.
However, their primary competitors include Turnstone Biologics, ImmunityBio, Immatics and 26 more.
Location: United States, Massachusetts, Cambridge
Employees: 1-10
Total raised: $70M
Founded date: 2022
Investors 3
| Date | Name | Website |
| 31.12.2022 | Alta Partn... | altapartne... |
| - | DC Investm... | dcinvestme... |
| 25.06.2022 | Insight Pa... | insightpar... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.06.2022 | Series A | $70M | Alta Partn... |
Mentions in press and media 1
| Date | Title | Description |
| 17.09.2026 | DEM Receives Over $1.2M Grant to Support Recreational Fishing and Boating | Published on Thursday, September 17, 2026 PROVIDENCE, RI – The Rhode Island Department of Environmental Management (DEM) has received a $1.2M grant from the U.S. Fish and Wildlife Service’s (USFWS) 2026 National Outreach and Communication P... |